Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

This study has been completed.
Information provided by:
Novartis Identifier:
First received: March 20, 2006
Last updated: December 17, 2007
Last verified: December 2007
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy. This study is designed to evaluate the safety and tolerability of add on therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)

Condition Intervention Phase
Alzheimer's Disease
Drug: Rivastigmine, memantine
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety and tolerability of treatment with memantine and rivastigmine, measured by the incidence of GI adverse events (nausea and vomiting)

Secondary Outcome Measures:
  • Whether patients on rivastigmine and memantine are able to reach and maintain higher doses of rivastigmine compared to historical data of rivastigmine monotherapy

Estimated Enrollment: 150
Study Start Date: March 2006
Study Completion Date: August 2007

Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a diagnosis of probable Alzheimer's disease;
  • Have an MMSE score between 10 and 20;
  • Must be able to swallow capsule/tablet;
  • Must have a caregiver who is able to attend all study visits;

Exclusion Criteria:

  • Have an advanced, severe, progressive, or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient at special risk;
  • Have a current diagnosis of active, uncontrolled seizure disorder;
  • Have a history within the past year or current diagnosis of cerebrovascular disease
  • Have a current diagnosis of severe or unstable cardiovascular disease;
  • Had a myocardial infarction (MI) within the last six months;
  • Have specific respiratory, digestive, renal, or endocrine disorders;
  • Have had previous treatment with rivastigmine or memantine;

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00305903

United States, New Jersey
Manchester, New Jersey, United States, 08759
Sponsors and Collaborators
Study Chair: Novartis 862-778-8300
  More Information Identifier: NCT00305903     History of Changes
Other Study ID Numbers: CENA713BUS32 
Study First Received: March 20, 2006
Last Updated: December 17, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Mental Disorders
Nervous System Diseases
Neurocognitive Disorders
Neurodegenerative Diseases
Anti-Dyskinesia Agents
Antiparkinson Agents
Cholinergic Agents
Cholinesterase Inhibitors
Dopamine Agents
Enzyme Inhibitors
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Protective Agents processed this record on May 24, 2016